Gossamer Bio (GOSS) Stock Price, Quote, News & History | Benzinga

SPY764.75+0.28%QQQ743.08+0.45%BTC/USD83,509.70−0.06%DIA509.90+0.27%GLD383.15+0.61%TLT77.15−0.81%

Gossamer Bio Inc (GOSS) Stock Price, Quote, News & History

GOSSNASDAQ

Trade with Public

Trade with Public

$11.85

0.272.33%

Last update: Oct 1, 4:05 AM

$11.85

0.272.33%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$11.85

Volume / Avg.

1.98K / 365.78K

Day Range

- - -

52 Wk Range

9.10 - 309.60

Market Cap

$72.48M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

51

Short Interest

15.73%

Days to Cover

5.07

Recent Gossamer Bio, Inc. News

Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones

Gossamer Bio Financing could provide up to $250 million, with much of the funding tied to seralutinib FDA milestones.

Akanksha Bakshi

This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock.

Avi Kapoor

This Honeywell Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts upgraded Grupo Cibest, Lufax, Honeywell, and Gossamer Bio. JBS also received an upgrade. See what analysts think.

Avi Kapoor

Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and revenue of $4.7 billion, leading to a 4.7% jump in pre-market trading. Other top gainers include C3is, INLIF, and Polar Power. FIEE and KIDZ were among the top losers.

Avi Kapoor

Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate

Gossamer Bio plans a September 2026 NDA filing for seralutinib following FDA feedback and reacquires global rights.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-162.63M

Investing Cash Flow (TTM)

174.48M

Financing Cash Flow (TTM)

3.20M

Free Cash Flow (TTM)

-162.63M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

15.05M

Analyst Trends and Forecast

1

1

May

1

Jun

2

Jul

1

Aug

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$56.26M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

0.73

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-441.10%

Earnings Yield % (FWD)

-48.87%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$15.37

Company Debt

Total Debt

$36.15M

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$41.15M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-